PMC:7253482 / 1856-2307 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"67","span":{"begin":325,"end":330},"obj":"Gene"},{"id":"76","span":{"begin":12,"end":22},"obj":"Species"},{"id":"77","span":{"begin":156,"end":162},"obj":"Species"},{"id":"79","span":{"begin":37,"end":46},"obj":"Disease"}],"attributes":[{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"Gene:43740568"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"Tax:2697049"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"Tax:9606"},{"id":"A79","pred":"tao:has_database_id","subj":"79","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T10","span":{"begin":335,"end":343},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T10","span":{"begin":12,"end":20},"obj":"Disease"},{"id":"T11","span":{"begin":12,"end":16},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T10","span":{"begin":156,"end":162},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T11","span":{"begin":312,"end":317},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T10","span":{"begin":335,"end":343},"obj":"Chemical"}],"attributes":[{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T8","span":{"begin":265,"end":274},"obj":"http://purl.obolibrary.org/obo/IDO_0000528"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T282","span":{"begin":0,"end":8},"obj":"RB"},{"id":"T283","span":{"begin":9,"end":11},"obj":"IN"},{"id":"T284","span":{"begin":12,"end":23},"obj":"NN"},{"id":"T285","span":{"begin":25,"end":30},"obj":"VBN"},{"id":"T286","span":{"begin":31,"end":36},"obj":"PRP-DOLLAR-"},{"id":"T287","span":{"begin":37,"end":46},"obj":"NN"},{"id":"T288","span":{"begin":47,"end":52},"obj":"NNS"},{"id":"T289","span":{"begin":52,"end":53},"obj":"-COMMA-"},{"id":"T290","span":{"begin":54,"end":57},"obj":"DT"},{"id":"T291","span":{"begin":58,"end":65},"obj":"JJ"},{"id":"T292","span":{"begin":66,"end":70},"obj":"NN"},{"id":"T293","span":{"begin":71,"end":73},"obj":"IN"},{"id":"T294","span":{"begin":74,"end":82},"obj":"VBN"},{"id":"T295","span":{"begin":83,"end":93},"obj":"NNS"},{"id":"T296","span":{"begin":94,"end":97},"obj":"CC"},{"id":"T297","span":{"begin":98,"end":106},"obj":"JJ"},{"id":"T298","span":{"begin":107,"end":115},"obj":"NNS"},{"id":"T299","span":{"begin":115,"end":116},"obj":"-COMMA-"},{"id":"T300","span":{"begin":117,"end":120},"obj":"CC"},{"id":"T301","span":{"begin":121,"end":126},"obj":"PRP-DOLLAR-"},{"id":"T302","span":{"begin":127,"end":135},"obj":"NN"},{"id":"T303","span":{"begin":136,"end":138},"obj":"TO"},{"id":"T304","span":{"begin":139,"end":147},"obj":"VB"},{"id":"T305","span":{"begin":148,"end":155},"obj":"IN"},{"id":"T306","span":{"begin":156,"end":162},"obj":"NNS"},{"id":"T307","span":{"begin":163,"end":166},"obj":"CC"},{"id":"T308","span":{"begin":167,"end":173},"obj":"IN"},{"id":"T309","span":{"begin":174,"end":181},"obj":"NNS"},{"id":"T310","span":{"begin":182,"end":193},"obj":"NN"},{"id":"T311","span":{"begin":193,"end":194},"obj":"-COMMA-"},{"id":"T312","span":{"begin":195,"end":200},"obj":"EX"},{"id":"T313","span":{"begin":201,"end":203},"obj":"VBZ"},{"id":"T314","span":{"begin":204,"end":206},"obj":"DT"},{"id":"T315","span":{"begin":207,"end":213},"obj":"JJ"},{"id":"T316","span":{"begin":214,"end":218},"obj":"NN"},{"id":"T317","span":{"begin":219,"end":222},"obj":"IN"},{"id":"T318","span":{"begin":223,"end":232},"obj":"JJ"},{"id":"T319","span":{"begin":233,"end":248},"obj":"NNS"},{"id":"T320","span":{"begin":249,"end":251},"obj":"TO"},{"id":"T321","span":{"begin":252,"end":258},"obj":"VB"},{"id":"T322","span":{"begin":259,"end":264},"obj":"DT"},{"id":"T323","span":{"begin":265,"end":274},"obj":"NNS"},{"id":"T324","span":{"begin":276,"end":283},"obj":"VBG"},{"id":"T325","span":{"begin":284,"end":291},"obj":"NN"},{"id":"T326","span":{"begin":292,"end":303},"obj":"NN"},{"id":"T327","span":{"begin":304,"end":311},"obj":"NNS"},{"id":"T328","span":{"begin":312,"end":317},"obj":"NN"},{"id":"T329","span":{"begin":318,"end":320},"obj":"IN"},{"id":"T330","span":{"begin":321,"end":324},"obj":"DT"},{"id":"T331","span":{"begin":325,"end":330},"obj":"NN"},{"id":"T332","span":{"begin":331,"end":332},"obj":"-LRB-"},{"id":"T333","span":{"begin":332,"end":333},"obj":"NN"},{"id":"T334","span":{"begin":333,"end":334},"obj":"-RRB-"},{"id":"T335","span":{"begin":335,"end":343},"obj":"NNS"},{"id":"T336","span":{"begin":344,"end":348},"obj":"WDT"},{"id":"T337","span":{"begin":349,"end":357},"obj":"VBP"},{"id":"T338","span":{"begin":358,"end":362},"obj":"IN"},{"id":"T339","span":{"begin":363,"end":366},"obj":"DT"},{"id":"T340","span":{"begin":367,"end":372},"obj":"JJ"},{"id":"T341","span":{"begin":373,"end":381},"obj":"NN"},{"id":"T342","span":{"begin":382,"end":385},"obj":"CC"},{"id":"T343","span":{"begin":386,"end":396},"obj":"VB"},{"id":"T344","span":{"begin":397,"end":400},"obj":"DT"},{"id":"T345","span":{"begin":401,"end":405},"obj":"JJ"},{"id":"T346","span":{"begin":406,"end":412},"obj":"NN"},{"id":"T347","span":{"begin":413,"end":415},"obj":"IN"},{"id":"T348","span":{"begin":416,"end":428},"obj":"VBG"},{"id":"T349","span":{"begin":429,"end":442},"obj":"NN"},{"id":"T350","span":{"begin":444,"end":449},"obj":"DT"}],"relations":[{"id":"R277","pred":"arg1Of","subj":"T283","obj":"T282"},{"id":"R279","pred":"arg2Of","subj":"T284","obj":"T283"},{"id":"R280","pred":"arg1Of","subj":"T313","obj":"T285"},{"id":"R281","pred":"arg2Of","subj":"T300","obj":"T285"},{"id":"R282","pred":"arg1Of","subj":"T288","obj":"T286"},{"id":"R283","pred":"arg1Of","subj":"T288","obj":"T287"},{"id":"R284","pred":"arg1Of","subj":"T288","obj":"T289"},{"id":"R285","pred":"arg2Of","subj":"T292","obj":"T289"},{"id":"R286","pred":"arg1Of","subj":"T292","obj":"T290"},{"id":"R287","pred":"arg1Of","subj":"T292","obj":"T291"},{"id":"R288","pred":"arg1Of","subj":"T292","obj":"T293"},{"id":"R289","pred":"arg2Of","subj":"T296","obj":"T293"},{"id":"R290","pred":"arg2Of","subj":"T295","obj":"T294"},{"id":"R291","pred":"arg1Of","subj":"T295","obj":"T296"},{"id":"R292","pred":"arg2Of","subj":"T298","obj":"T296"},{"id":"R293","pred":"arg1Of","subj":"T298","obj":"T297"},{"id":"R294","pred":"arg1Of","subj":"T300","obj":"T299"},{"id":"R295","pred":"arg1Of","subj":"T289","obj":"T300"},{"id":"R296","pred":"arg2Of","subj":"T302","obj":"T300"},{"id":"R297","pred":"arg1Of","subj":"T302","obj":"T301"},{"id":"R298","pred":"arg1Of","subj":"T304","obj":"T303"},{"id":"R299","pred":"modOf","subj":"T302","obj":"T303"},{"id":"R300","pred":"arg1Of","subj":"T304","obj":"T305"},{"id":"R301","pred":"arg2Of","subj":"T306","obj":"T305"},{"id":"R302","pred":"arg1Of","subj":"T285","obj":"T307"},{"id":"R303","pred":"arg2Of","subj":"T308","obj":"T307"},{"id":"R304","pred":"arg1Of","subj":"T313","obj":"T308"},{"id":"R305","pred":"arg2Of","subj":"T310","obj":"T308"},{"id":"R306","pred":"arg1Of","subj":"T310","obj":"T309"},{"id":"R307","pred":"arg1Of","subj":"T313","obj":"T311"},{"id":"R308","pred":"arg1Of","subj":"T312","obj":"T313"},{"id":"R309","pred":"arg2Of","subj":"T316","obj":"T313"},{"id":"R310","pred":"arg1Of","subj":"T316","obj":"T314"},{"id":"R311","pred":"arg1Of","subj":"T316","obj":"T315"},{"id":"R312","pred":"arg1Of","subj":"T316","obj":"T317"},{"id":"R313","pred":"arg2Of","subj":"T319","obj":"T317"},{"id":"R314","pred":"arg3Of","subj":"T321","obj":"T317"},{"id":"R315","pred":"arg1Of","subj":"T319","obj":"T318"},{"id":"R316","pred":"arg1Of","subj":"T321","obj":"T320"},{"id":"R317","pred":"arg1Of","subj":"T319","obj":"T321"},{"id":"R318","pred":"arg2Of","subj":"T323","obj":"T321"},{"id":"R319","pred":"arg1Of","subj":"T323","obj":"T322"},{"id":"R320","pred":"arg1Of","subj":"T328","obj":"T324"},{"id":"R321","pred":"arg1Of","subj":"T328","obj":"T325"},{"id":"R322","pred":"arg1Of","subj":"T328","obj":"T326"},{"id":"R323","pred":"arg1Of","subj":"T328","obj":"T327"},{"id":"R324","pred":"arg1Of","subj":"T328","obj":"T329"},{"id":"R325","pred":"arg2Of","subj":"T335","obj":"T329"},{"id":"R326","pred":"arg1Of","subj":"T335","obj":"T330"},{"id":"R327","pred":"arg1Of","subj":"T335","obj":"T331"},{"id":"R328","pred":"arg1Of","subj":"T335","obj":"T332"},{"id":"R329","pred":"arg2Of","subj":"T333","obj":"T332"},{"id":"R330","pred":"arg3Of","subj":"T334","obj":"T332"},{"id":"R331","pred":"arg1Of","subj":"T335","obj":"T336"},{"id":"R332","pred":"arg1Of","subj":"T335","obj":"T337"},{"id":"R333","pred":"arg1Of","subj":"T337","obj":"T338"},{"id":"R334","pred":"arg2Of","subj":"T341","obj":"T338"},{"id":"R335","pred":"arg1Of","subj":"T341","obj":"T339"},{"id":"R336","pred":"arg1Of","subj":"T341","obj":"T340"},{"id":"R337","pred":"arg1Of","subj":"T337","obj":"T342"},{"id":"R338","pred":"arg2Of","subj":"T343","obj":"T342"},{"id":"R339","pred":"arg1Of","subj":"T335","obj":"T343"},{"id":"R340","pred":"arg2Of","subj":"T346","obj":"T343"},{"id":"R341","pred":"arg1Of","subj":"T346","obj":"T344"},{"id":"R342","pred":"arg1Of","subj":"T346","obj":"T345"},{"id":"R343","pred":"arg1Of","subj":"T346","obj":"T347"},{"id":"R344","pred":"arg2Of","subj":"T348","obj":"T347"},{"id":"R345","pred":"arg2Of","subj":"T349","obj":"T348"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T10","span":{"begin":335,"end":343},"obj":"Body_part"}],"attributes":[{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T10","span":{"begin":335,"end":343},"obj":"Chemical"}],"attributes":[{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T17","span":{"begin":12,"end":20},"obj":"Species"},{"id":"T18","span":{"begin":12,"end":16},"obj":"Species"},{"id":"T19","span":{"begin":156,"end":162},"obj":"Species"}],"attributes":[{"id":"A17","pred":"ncbi_taxonomy_id","subj":"T17","obj":"NCBItxid:694009"},{"id":"A18","pred":"ncbi_taxonomy_id","subj":"T18","obj":"NCBItxid:694009"},{"id":"A19","pred":"ncbi_taxonomy_id","subj":"T19","obj":"NCBItxid:9605"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T14","span":{"begin":25,"end":275},"obj":"Sentence"},{"id":"T15","span":{"begin":276,"end":443},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T10","span":{"begin":12,"end":20},"obj":"Disease"},{"id":"T11","span":{"begin":12,"end":16},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"76","span":{"begin":12,"end":22},"obj":"Species"},{"id":"79","span":{"begin":37,"end":46},"obj":"Disease"},{"id":"77","span":{"begin":156,"end":162},"obj":"Species"},{"id":"67","span":{"begin":325,"end":330},"obj":"Gene"}],"attributes":[{"id":"A76","pred":"pubann:denotes","subj":"76","obj":"Tax:2697049"},{"id":"A79","pred":"pubann:denotes","subj":"79","obj":"MESH:D003643"},{"id":"A77","pred":"pubann:denotes","subj":"77","obj":"Tax:9606"},{"id":"A67","pred":"pubann:denotes","subj":"67","obj":"Gene:43740568"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T714","span":{"begin":331,"end":343},"obj":"Protein"}],"attributes":[{"id":"A714","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9UIP0"},{"id":"A715","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9UIN9"},{"id":"A716","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9UIN8"},{"id":"A717","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9UIN7"},{"id":"A718","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9UIN6"},{"id":"A719","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9UBH8"},{"id":"A720","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9NRH8"},{"id":"A721","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9NRH7"},{"id":"A722","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9NRH6"},{"id":"A723","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9NRH5"},{"id":"A724","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9NRH4"},{"id":"A725","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9NPG5"},{"id":"A726","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9NPE0"},{"id":"A727","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q9NP52"},{"id":"A728","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q95IF9"},{"id":"A729","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q8N5P3"},{"id":"A730","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q8IZU6"},{"id":"A731","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q8IZU5"},{"id":"A732","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q8IZU4"},{"id":"A733","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q86Z04"},{"id":"A734","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q7YR44"},{"id":"A735","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q7LA71"},{"id":"A736","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q7LA70"},{"id":"A737","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q5STD2"},{"id":"A738","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q5SQ85"},{"id":"A739","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q1XI16"},{"id":"A740","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q1XI12"},{"id":"A741","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/Q15517"},{"id":"A742","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/O43509"},{"id":"A743","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/O19084"},{"id":"A744","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/B0UYZ7"},{"id":"A745","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/B0S7V2"},{"id":"A746","pred":"uniprot_id","subj":"T714","obj":"https://www.uniprot.org/uniprot/A5A6L9"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}

{"project":"LitCovid-sentences","denotations":[{"id":"T14","span":{"begin":25,"end":275},"obj":"Sentence"},{"id":"T15","span":{"begin":276,"end":443},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"recently of SARS-CoV-24. Given their mortality rates, the current lack of targeted treatments and licensed vaccines, and their capacity to transmit between humans and across species barriers5,6, there is an urgent need for effective countermeasures to combat these pathogens. Ongoing vaccine development efforts focus on the spike (S) proteins that protrude from the viral envelope and constitute the main target of neutralizing antibodies7,8.\nThese t"}